FDA Approval Alert: The Need-to-Know | Zanubrutinib Tablets in Multiple Hematologic Indications

In June 2025, the FDA approved a tablet formulation of zanubrutinib across 5 hematologic indications for which zanubrutinib capsules earned approval.

Zanubrutinib tablets were found to have the same efficacy and safety as capsules based on 2 single-dose, open-label randomized phase 1 studies.
FDA Approves Zanubrutinib Tablets in Multiple Hematologic Indications
Article
Jun 12, 2025 12:30 AM
Zanubrutinib tablets were found to have the same efficacy and safety as capsules based on 2 single-dose, open-label randomized phase 1 studies.